Difference between revisions of "Pegaspargase (Oncaspar)"
m |
|||
| Line 10: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
''No regimen currently listed on HemOnc.org directly references this drug. However, it is often substituted for [[Asparaginase (Elspar) | L-asparaginase]] in many chemotherapy regimens, due to ease of administration.'' | ''No regimen currently listed on HemOnc.org directly references this drug. However, it is often substituted for [[Asparaginase (Elspar) | L-asparaginase]] in many chemotherapy regimens, due to ease of administration.'' | ||
| + | *[[Acute lymphocytic leukemia]] | ||
| + | *[[T-cell lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 23: | Line 25: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Intramuscular Chemotherapy]] | ||
| + | [[Category:Intravenous Chemotherapy]] | ||
| + | |||
[[Category:Enzymes]] | [[Category:Enzymes]] | ||
[[Category:Acute lymphocytic leukemia medications]] | [[Category:Acute lymphocytic leukemia medications]] | ||
[[Category:T-cell lymphoma medications]] | [[Category:T-cell lymphoma medications]] | ||
[[Category:Drugs FDA approved in 1994]] | [[Category:Drugs FDA approved in 1994]] | ||
Revision as of 23:51, 12 November 2014
Also known as PEG-L-asparaginase, Peg-asparginase, Pegasparaginase.
General information
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase. The Oncaspar formulation involves L-asparaginase (L-asparagine amidohydrolase) being covalently conjugated to monomethoxypolyethylene glycol (mPEG), increasing its half-life and reducing the risk of hypersensitivity reactions in patients who have history of hypersensitivity to Asparaginase (Elspar).[1][2]
Route: IV, IM
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
No regimen currently listed on HemOnc.org directly references this drug. However, it is often substituted for L-asparaginase in many chemotherapy regimens, due to ease of administration.
Patient drug information
- Pegaspargase (Oncaspar) patient drug information (Chemocare)[3]
- Pegaspargase (Oncaspar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2/1/1994: Initial FDA approval